Trial Profile
Multicenter, Open-label, Non-interventional Study (NIS) to Evaluate Patient's Satisfaction and Preference, the Usability of DuoResp SPIROMAX and the Impact on Clinical Effects, in the Daily Routine of Asthma and COPD Treatment
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Budesonide/formoterol (Primary)
- Indications Asthma; Chronic obstructive pulmonary disease
- Focus Therapeutic Use
- Sponsors Teva Pharmaceutical Industries
- 03 Nov 2016 Status changed from active, no longer recruiting to completed.
- 13 Apr 2016 Planned End Date changed from 1 Dec 2016 to 1 Sep 2016.
- 02 Mar 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016 as per ClinicalTrials.gov record.